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The  aim  of the  present  work  was  to  develop  a  biochemical,  histologic  and  immunohis-
tochemical  study  about  the  potential  hepatotoxic  effect  of  d-limonene  – a component
of  volatile  oils  extracted  from  citrus  plants.  Blood  alkaline  phosphatase  (ALP),  aspartate
aminotransferase  (AST)  and  alanine  aminotransferase  (ALT)  from  d-limonene-treated  ani-
mals  were  determined  and  compared  to morphologic  hepatic  lesions  in  order  to investigate
the  possible  physiopathologic  mechanisms  involved  in  the liver  toxicity,  in  experimental
animals  treated  with  d-limonene.  Wistar  rats were  randomly  divided  into  seven  groups:
two control  groups  (untreated  or receiving  only  vehicle,  tween-80);  one  positive  control
(vehicle);  two experimental  groups  treated  with  d-limonene  at doses  of  25  mg/kg/day  and
75 mg/kg/day  for 45 days,  and  two other  groups  treated  with  the same  doses  for  30  days
and kept  under  observation  during  30  more  days.  Biochemical  data  showed  signiﬁcant
reduction  in ALT  levels  in the animals  treated  with 75 mg/kg  of d-limonene.  Histological
analysis  revealed  some  hepatocyte  morphological  lesions,  including  hydropic  degenera-
tion, microvesicular  steatosis  and  necrosis,  Kupffer  cell  hyperplasia  and  incipient  ﬁbrosis.  By
immunohistochemistry,  inﬂux  of  T (CD3+)  and  cytotoxic  (CD8+)  lymphocytes  was  observed
in the  rats  treated  with  d-limonene  at both  dose  levels.  In conclusion,  it is  possible  that
d-limonene  has  been  directly  responsible  for hepatic  parenchymal  and  matrix  damage
following  subchronic  treatment  with  d-limonene.
rs.  Publ
Y-NC-N© 2015  The  Autho
the  CC  B
1. Introductiond-Limonene(1-methyl-4-(1-methylethenyl)-cyclohex-
ene) is a monocyclic monoterpene found as the major
Abbreviations: ALP, alkaline phosphatase; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; HE, hematoxylin–eosin.
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constituent in several citrus oils such as lemon and orange
[29], and other essential oils [5] known to be employed
as ﬂavoring agents and fragrances in household products
[4,22,9]. It is used clinically to dissolve cholesterol-
containing gallstones and for relief of gastroesophageal
reﬂux and heartburn due to its gastric acid neutralizing
effect. It also shows chemopreventive activity against
many types of cancers, including breast and colorectal
cancers [8,23], and has anti-oxidant property [19,28].
Orally administered d-limonene is rapidly absorbed in
the gastrointestinal tract in animals and humans, being
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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ubsequently distributed to different parts of the body,
uch as the liver, lung and kidney, where it is readily
etabolized [7,23].
The liver is the most important organ for metaboliza-
ion and elimination of substances, but it is also a frequent
arget for toxic aggressions. Over the years, there has
een increasing evidence that plant-derived components
an cause hepatotoxicity. For instance, the occurrence of
cute hepatitis and acute liver failure has been attributed
o the use of some plants, such as the popular kava-
ava [15]. Acute and chronic experiment protocols have
videnced that d-limonene exhibits fairly low toxicity [11],
lthough (+)-limonene was shown to cause renal toxicity
n male rats, probably related to the high expression of
2u-globulin in the liver [14,22]. In view of the widespread
se of d-limonene in food products, this work was aimed
t investigating the cytotoxic effects and identifying hepa-
ocellular lesions of this substance after administration to
istar rats.
. Materials and methods
.1. Animals and treatments
Fifty-eight male Wistar rats (Rattus norvegicus Berken-
out, 1769) (90 days old and weighing about 280–350 g)
ere obtained from the vivarium Prof. Dr. Thomas George
f the Federal University of Paraíba (UFPB, João Pessoa,
araíba, Brazil), where they were born and bred. The
nimals were housed in polyethelene cages and kept
nder standard laboratory conditions at a temperature of
3 ± 2◦ C, with a 12 h light/12 h dark photoperiod. They
ere fed on rat chow pellets (Purina) and received water
d libitum. All animals were deprived of food and water
0 min  before the beginning of the experiments. The exper-
mental protocol was approved by the Ethical Committee of
FPB, which follows the international principles in ethics
or animal experimentation.
Wistar rats were randomly divided into seven groups as
hown in Table 1, and treated by gavage and once daily for
0 or 45 days. The treatment groups received d-limonene
Sigma-Aldrich, USA), diluted in 0.2% tween-80 (Sigma-
ldrich, USA), at the dose levels of 25 mg/kg and 75 mg/kg
f body weight. The lower dose was based on the low-
st dose showing activity on the central nervous system
eported in the literature, while the higher dose was related
o the occurrence of hepatomegaly as reported previously
12]. Another treatment group used as a positive control
eceived ethanol (diluted in 20% distilled water) at a dose of
able 1
nimal groups and treatments.
Group Drug 
I – 
II  Tween-80 
III  20% ethanol 
IV  25 mg/kg of d-limonene 
V  75 mg/kg of d-limonene 
VI  25 mg/kg of d-limonene 
VII  75 mg/kg of d-limonene ports 2 (2015) 482–488 483
3.5 ml/kg of body weight following the same protocol as the
other treatment groups. The control group comprised one
group that received no treatment and another that received
tween-80.
2.2. Bioassay
During the experiment, the animals were observed for
detection of clinical signs of toxicity. The animals from
group I to V were sacriﬁced on the 46th day, while ani-
mals from groups VI and VII were sacriﬁced 30 days after
the end of treatment. The animals were killed by cervical
dislocation and, immediately after death, they underwent
laparotomy for the removal, weighing and histopatho-
logical analysis of liver, kidneys, lungs and heart. The
organs were ﬁxed in formalin (10% formaldehyde solution),
embedded in parafﬁn, and sectioned at 3.0 m thickness
for routine hematoxylin–eosin (HE) staining. The staining
with picrosirius red was employed for collagen detection
and the Perls’ technique was used for the investigation
of hepatosiderosis. The morphological evaluation was  car-
ried out in a light microscope (Nikon Eclipse E200). Prior
to autopsy, blood was drawn by cardiac puncture for bio-
chemical analysis of serum alkaline phosphatase (ALP),
aspartate aminotransferase (AST), and alanine aminotrans-
ferase (ALT) using kinetic methods (Toxicology Laboratory,
UFPB).
The hepatic lesions were identiﬁed according to
the following criteria: (1) hydropic degeneration, (2)
microvesicular steatosis, (3) necrosis (hypostained or
absent nucleus, intense cytoplasmic eosinophilia, and
destruction or loss of the architecture of the hepatocyte
cord), and (4) apoptosis. A system of scores to grade liver
lesions was employed following the criteria set by the
Brazilian Society of Pathology and the Brazilian Society of
Hepatology (1999) (Table 2).
The degree of hepatic siderosis was evaluated accord-
ing to [21] as follows: (1) absence of hepatic iron, (2) iron
particles visible at 400× magniﬁcation, (3) iron particles
visible at 100× magniﬁcation, (4) iron particles visible at
25× magniﬁcation, and (5) accumulation of iron particles
visible at 10× magniﬁcation or with the naked eye.
Immunohistochemistry was  performed in order to ver-
ify the exact nature of the inﬂammatory mononuclear
populations. The histological sections underwent anti-
genic recovery by using citrate buffer (pH 6.0), heated
in water bath at a temperature of 95 ◦C for 20 min. After
cooling, they were blocked with peroxidase blocking solu-
tion (3% hydrogen peroxide) following primary antibody
N Duration of treatment (days)
8 –
10 45
10 45
10 45
10 45
5 30
5 30
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Table  2
Criteria for histological evaluation of the degree of ﬁbrosis (A), degree of portal lymphocyte inﬁltration (B), degree of periportal and periseptal lymphocyte
inﬁltration (C) and degree of necroinﬂammatory activity in the hepatic tissue (D).
A B
Score Lobular architecture Degree Septal and portal inﬂammatory inﬁltrate
F0 Normal (absence of ﬁbrosis) 0 Absent of rare portal lymphocytes
F1  Fibrous extension of portal spaces 1 Discreet increase in the number of portal
lymphocytes
F2  Fibrous extension of portal spaces with portal-portal septa 2 Moderate increase in the number of portal
lymphocytes
F3  Fibrous extension of portal spaces with portal-portal and
portal-central septa, with possible nodule formation
3 Marked increase in the number of portal
lymphocytes
F4  Cirrhosis with predominant nodular areas in relation to
the remaining lobules
4 Strongly marked increase in the number of
portal lymphocytes
C  D
Degree Septal and portal inﬂammatory activity Degree Necroinﬂammatory activity
0 Absence of lesions in the interface portal
space/parenchyma
0 Normal and isomorphic hepatocytes
1  Lymphocyte extravasations not characterizing piecemeal
necrosis
1 Discreet hepatocytic alterations (tumefaction
or acidophilic retraction) with
lymphohistiocytic inﬁltrate and rare necrotic
areas
2  Discreet piecemeal necrosis 2 Focal hepatocyte necrosis surrounded by
lymphohistiocytic aggregate
3  Moderate piecemeal necrosis 3 Focal hepatocyte necrosis surrounded by
lymphohistiocytic aggregate associated with
limited areas of conﬂuent necrosis
4  Piecemeal necrosis in extensive areas of portal spaces 4 Focal hepatocyte necrosis surrounded byincubation for 12 h (dilution 1:200). The antibodies used
were: CD3 (anti-human T cells, clone UCHT1), CD8 (anti-
human cytotoxic T cells, clone M 707), and macrophage
marker (clone HAM-56). The sections were then incubated
with the secondary antibody from LSAB kit for 30 min  and
the ampliﬁer from the same kit for another 30 min. The
immunoreactions were developed with diaminobenzidine
and counterstained with Harris hematoxylin for observa-
tion under a light microscope.
2.3. Statistical analysis
The histopathological data were analyzed for statistical
signiﬁcance using one-way analysis of variance (ANOVA)
followed by Kruskal–Wallis. The multiple comparison of
the weights and biochemical scores were analyzed by
ANOVA followed by Tukey’s test. The difference between
groups was considered signiﬁcant when P < 0.05.
3. Results
3.1. Biochemical analysis
After treatment, ALT levels were signiﬁcantly reduced
in animals exposed to the highest dose of d-limonene
(75 mg/kg/day for 45 days) when compared to control val-
ues, while AST and ALP serum levels were not altered.
Serum levels of AST, ALT and ALP 45 days after the end of
treatment were also comparable to that of control animals
(Table 3).lymphohistiocytic aggregate associated with
limited areas of extensive/multiple conﬂuent
necrosis
3.2. Morphological evaluation
The necroscopic examination of the abdominal cavity
did not reveal any signs of portal hypertension. Kidneys,
lungs and heart were macroscopically and microscopically
normal. No change in the weight of these organs as well
as the weight of the liver was  observed in the d-limonene-
treated groups when compared to the control groups (data
not shown). During the experimental procedure, no deaths,
piloerection, locomotor activity alteration or any other
clinical sign of toxicity were observed in the treated ani-
mals.
3.3. Liver histopathology
The liver of control rats showed normal histological
architecture and the presence of a small number of resident
lymphocytes in the portal connective stroma (Fig. 1a). In
the 25 and 75 mg/kg d-limonene-treated, the histopatho-
logical analysis revealed the occurrence of hepatocellular
lesions, such as hydropic degeneration, microvesicular
steatosis, apoptosis, necrosis (Fig. 1b) or stromal ﬁbrosis,
showing the formation of ﬁne connective septa in perisi-
nusoidal spaces (Fig. 1c). Discreet (degree 1) or moderate
(degree 2) inﬂammation was  observed in the hepatic lobes
(parenchyma) (Fig. 1d) and/or portal spaces (Fig. 1e and
f). The lesions were always associated with inﬂammatory
processes characterized by mononuclear cells exudation
(lymphocytes and histiocytes) in the portal and lobular
compartments.
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Table  3
AST, ALT and ALP serum levels in control, ethanol and d-limonene-treated rats after 45 days of treatment.
Enzyme (UI/L) Group
II III IV V
AST 168.6 ± 15.8 171.2 ± 8.7 150.2 ± 10.4 147.2 ± 11.4
ALT  66.7 ± 4.5 65.1 ± 3.7 63.2 ± 3.7 50.8 ± 3.0*
ALP 153.1 ± 20.7 123.1 ± 5.4 118.7 ± 8.5 104.5 ± 11.5
Data expressed by mean ± standard error (S.E.M).
* P < 0.05, Tukey’s test II – control (tween-80), III – 20% ethanol, IV – 25 mg/kg, and V – 75 mg/kg.
Fig. 1. Liver of control and d-limonene treated rats.
Table 4
Degree of portal inﬂammation and parenchymal (lobular) of control, ethanol and d-limonene-treated rats during 30 days and 45 days.
Group Degree of portal hepatic inﬂammation Degree of portal hepatic inﬂammation Treatment (days)
0 1 2 3 or 4 0 1 2 3 or 4
I 2 (25%) 6 (75%) 0 0 5 (62.5%) 3 (37.5%) 0 0 -
II  3 (30%) 7 (70%) 0 0 6 (60%) 4 (40%) 0 0 45
III  0 6 (60%) 4 (40%) 0 4 (40%) 2 (20%) 4 (40%) 0 45
IV  0 5 (50%) 5 (50%) 0 1 (10%) 3 (30%) 6 (60%) 0 45
V  2 (20%) 7 (70%) 1 (10%) 0 0 5 (50%) 5 (50%) 0 45
VI  0 3 (60%) 2 (40%) 0 1 (20%) 4 (80%) 0 0 30
VII  1 (20%) 4 (80%) 0 0 0 3 (60%) 2 (40%) 0 30
I – control (without treatment), II – tween-80, III – 20% ethanol, IV – 25 mg/kg, V – 75 mg/kg, VI – 25 mg/kg, VII – 75 mg/kg.
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ation (Fig. 2. Degree of hepatic portal inﬂamm
According to the scores presented in Table 2, the lym-
phocytary reaction restricted to the portal space was
considered as discreet (degree 1) in more than 50% of the
livers analyzed. No portal/septal degree 3 or 4 of inﬂam-
mation was observed (Table 4).
The intensity of lymphocytary inﬂammatory inﬁltra-
tion in the hepatic parenchyma (lobular inﬂammation) was
characterized as discreet (degree 1), occurring predomi-
nantly in groups VI and VII (treated with 25 mg/kg and
75 mg/kg of d-limonene, respectively, for 30 days and sac-
riﬁced 30 days after the end of treatment), and as moderate
(degree 2) specially in animals from group IV (treated with
25 mg/kg d-limonene for 45 days) (Table 4).
The degree of portal inﬂammatory response was sig-
niﬁcantly different in group IV (treated with 25 mg/kg
d-limonene for 45 days) when compared to group II (con-
trol – tween-80) (Fig. 2), while the degree of lobular
inﬂammatory activity was signiﬁcant between groups IV
and V (treated with 25 mg/kg and 75 mg/kg of d-limonene,
respectively, for 45 days) and the control groups (with-
out treatment and tween-80) (Fig. 2). None of the animals
from control or treated groups exhibited hepatic siderosis,
according to the classiﬁcation adopted in this experimental
protocol.
3.4. Immunohistochemical analysisThe results revealed that the inﬂammatory inﬁltrates
in the hepatic tissue exhibited histiocytic elements asso-
ciated to slight hyperplasia of Kupffer cells as evidenced
by the macrophage marker (clone HAM-56). The inﬁltrate
Fig. 3. Histologicaa) and parenchymal inﬂammation (b).
consisted predominantly of T cells as indicated by CD3
(anti-human T cells, clone UCHT1), and CD8 (anti-human
cytotoxic T cells, clone M 707) (Fig. 3a and b).
4. Discussion
Food is the major source of exposure to limonene (96%).
According to the Committee of Experts of the FAO, WHO
Food Additives values for daily intake of d-limonene range
of 0–1.5 mg/kg body weight per day. Citrus juices repre-
sented a daily intake of 1 mg/kg body weight per day in
adults and 2 mg/kg for children [10].
In this study, the serum levels of ALT, AST and ALP
obtained in all of the d-limonene-treated animals do not
indicate hepatic disease. The alterations found in these
animals would only be considered signiﬁcant if the amino-
transferases values were at least three times higher than
the values obtained in the control groups [15]. However,
the alterations in serum levels of the biochemical indica-
tors do not exclude the possibility of occurrence of hepatic
lesions when the organism is exposed to potential hepato-
toxic agents.
The histological assessment of the liver showed the
presence of discreet or moderate lesions exhibiting leuko-
cyte inﬁltration, hydropic degeneration and/or necrosis.
The hydropic degeneration refers to the occurrence of
reversible intracellular edema as a consequence of toxic,
infectious or immune aggressions. The increase in cell
volume and clearness is associated with the formation
of microvacuoles or clear cytoplasmic spaces as a result
of the action of injurious agents that cause intracellular
l section.
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ccumulation of sodium and increase in water content [13].
hese lesions were observed in the liver of all d-limonene-
reated rats at both dose levels (25 and 75 mg/kg), but not
n control and ethanol-treated animals. The rats from the
-limonene treated group killed 30 days after the end of
reatment also failed to exhibit these features, reﬂecting
he reversibility of this type of cellular lesion. The hydropic
egeneration observed in all of the groups treated with
-limonene elicits a possible direct cellular aggression;
herefore, it is reasonable to assume that the metabo-
ization of the terpene d-limonene generated a potential
oxious substance to the mitochondrial functioning, stimu-
ating speciﬁc immune reactions. Hepatotoxic metabolites
an be produced through the oxidative metabolism of drugs
phase 1) with the participation of CYP450 enzymatic sys-
em, and the conjugative metabolism of drugs (phase 2)
1,2,26]. Phase 1 mechanisms are probably implicated in
he toxic aggressions induced by d-limonene since this ter-
ene is metabolized in rats and humans into oxygenated
ompounds such as dihydroperillic acid, perillic acid, and
imonene-8-9-diol [3,17,26,20]. Moreover, earlier studies
ave shown the increase in CYP450 activity in rodents
reated orally and intraperitoneally with d-limonene [1,2].
eactive metabolites that damage mitochondrial respira-
ion and ATP production, and generate oxygen reactive
pecies, inhibiting -oxidation, can cause steatosis; how-
ver, this kind of lesion was not signiﬁcantly expressed in
his study.
Steatosis or fatty liver was observed in a small number of
nimals from the d-limonene- and ethanol-treated groups.
n the other hand, the occurrence of signiﬁcant inﬂamma-
ory reactions with the presence of mononuclear cells was
etected in most of the animals treated with d-limonene
uring 30 or 45 days. The inﬂammatory cells were found
specially in the parenchymal, intermediate and peripor-
al areas, as well as the portal spaces, indicating a possible
epatotoxic effect of d-limonene in rats. The drug-induced
iver injury can cause primary damage, i.e. necrosis or apo-
tosis, or even cell death as speciﬁc immune response with
he participation of cytotoxic T lymphocytes. The hepatic
ecroinﬂammatory lesions observed in the d-limonene-
reated groups probably resulted from the hypersensitivity
rocess as evidenced by the immunohistochemical evalua-
ion which demonstrated the prevalence of T lymphocytes
CD3 positive) in the parenchymal mononuclear inﬁltra-
ion. These ﬁnding, however, do not agree with the reports
y [27], which do not indicate the occurrence of abnormal
iver histopathology in rats treated orally with doses of 30
nd 75 mg/kg of d-limonene. As the mobilization of T cells
epresents one aspect of d-limonene hepatic inﬂamma-
ory lesion, it is expected that a speciﬁc immune response
nvolving cytotoxic lymphocytes with concomitant release
f cytokines may  occur as a consequence of the covalent
inding between reactive metabolites and proteins, result-
ng in the formation of neo-antigens or haptens [18,16]. In
he present experimental model, the hepatic parenchymal
nﬂammatory lesions were less signiﬁcant in the animals
rom groups VI and VII (treated with 25 and 75 mg/kg d-
imonene and killed 30 days after the end of treatment),
iving further support to the hypothesis that in the rat
-limonene has an intrinsic hepatotoxic potential.ports 2 (2015) 482–488 487
Insipient ﬁbrosis was  observed in d-limonene-treated
animals without the occurrence of connective tissue
growth of the portal spaces (degree F0). Special stain-
ing methods (picrosirius) evidenced the presence of ﬁne
perisinusoidal collagen septa associated to the lobular
inﬂammatory process. Such alterations were similar to
those observed in parenchymal hepatic inﬂammation
caused by various factors, including alcoholic intoxication
[6].
However, these ﬁndings cannot be relevant to humans,
considering that the doses used were higher, as compared
to No-observed-adverse-effect level (NOAEL) reported by
[11]. In practice, human exposure to limonene, via inhala-
tion of the environment, pharmaceuticals, among other
uses, it would not be sufﬁcient to produce such hepatotoxic
effects.
Liver injury as a result of alcohol consumption has been
experimentally demonstrated in rodents and humans to
the extent that in rodents the intragastric administration of
ethanol has been shown to cause steatosis, necrosis, inﬂam-
mation and hepatic ﬁbrosis [24,25]. Ethanol-treated rats
(3.5 ml/kg/day) were used as a positive control, and like
the d-limonene-treated group, a small number of animals
exhibited steatosis, showing isolated small fat droplets
in the hepatocytes. Furthermore, the necroinﬂammatory
activity detected in the hepatic parenchyma of the ethanol
group was  also similar to that displayed by the d-limonene
treatment groups.
5. Conclusion
In conclusion, the hepatocellular injuries reported in
this study are probably related to the direct toxic effects
of d-limonene reactive metabolites. The inﬂammatory
mononuclear afﬂux can be interpreted as a manifestation
of the immune response induced by these metabolites, and
the hyperplasia of Kupffer cells could be indicated as a
contributing factor to the stimulation of the lymphocytic
immune response.
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